The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema, HAE. NTLA-2002 is a wholly owned investigational in vivo CRISPR ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

The latter involved NTLA-2002. This treatment addresses hereditary angioedema (HAE). It’s a genetic condition that causes severe swelling. The Street reacted to those test results by knocking 20 ...

The company expects to release more data from Phase 1/2 studies this year and is prioritizing clinical execution for NTLA-2002 and Nex-Z. The company expects a Biologics License Application (BLA ...